108,762 Shares in Immunocore Holdings plc (NASDAQ:IMCR) Bought by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. acquired a new stake in Immunocore Holdings plc (NASDAQ:IMCR) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 108,762 shares of the company’s stock, valued at approximately $3,686,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. NEOS Investment Management LLC bought a new stake in shares of Immunocore in the 4th quarter valued at about $262,000. Tidal Investments LLC bought a new stake in Immunocore in the first quarter valued at approximately $423,000. China Universal Asset Management Co. Ltd. raised its holdings in Immunocore by 69.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock worth $430,000 after purchasing an additional 2,721 shares during the period. Nan Fung Group Holdings Ltd bought a new position in shares of Immunocore during the first quarter worth $439,000. Finally, DNB Asset Management AS boosted its position in shares of Immunocore by 35.0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after purchasing an additional 1,868 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Price Performance

Shares of NASDAQ IMCR opened at $31.40 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 5.17 and a quick ratio of 5.15. The business has a 50-day moving average of $35.94 and a 200-day moving average of $45.28. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -25.74 and a beta of 0.73. Immunocore Holdings plc has a fifty-two week low of $29.76 and a fifty-two week high of $76.98.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.25. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The firm had revenue of $75.40 million during the quarter, compared to the consensus estimate of $74.58 million. During the same period last year, the company earned ($0.37) earnings per share. The business’s revenue was up 26.2% compared to the same quarter last year. As a group, sell-side analysts predict that Immunocore Holdings plc will post -1.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

IMCR has been the topic of several recent analyst reports. JPMorgan Chase & Co. reduced their target price on Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a report on Wednesday, July 10th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Immunocore in a report on Tuesday, September 17th. Needham & Company LLC reduced their price target on shares of Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. Finally, Barclays reduced their target price on shares of Immunocore from $92.00 to $66.00 and set an “overweight” rating for the company in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, Immunocore presently has an average rating of “Moderate Buy” and an average target price of $80.40.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.